Big Pharma Split Corp Class A (PRM) — Cash Flow Reinvestment Rate
Big Pharma Split Corp Class A (PRM) has a Cash Flow Reinvestment Rate of 0.00x as of September 2023, reinvesting CA$0.00 (capex CA$0.00 ) from operating cash flow of CA$644.28K. Check earnings quality score of Big Pharma Split Corp Class A to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Big Pharma Split Corp Class A Cash Flow Reinvestment Rate (2018–2023)
Historical reinvestment intensity for Big Pharma Split Corp Class A across 5 annual periods. Explore Big Pharma Split Corp Class A long-term investment allocation to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Big Pharma Split Corp Class A (2018–2023)
Year-by-year capital reinvestment analysis for Big Pharma Split Corp Class A. For live market cap and broader valuation context, see PRM company net worth.
| Year | Reinvestment Rate | Total Reinvested (CAD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.00x | CA$3.00 | CA$11.86 Million | CA$3.00 | — |
| 2022 | 0.00x | CA$0.00 | CA$1.13 Million | CA$0.00 | ▼ -100.0% |
| 2020 | 0.00x | CA$3.00 | CA$4.35 Million | CA$3.00 | — |
| 2019 | 0.00x | CA$0.00 | CA$8.68 Million | CA$0.00 | — |
| 2018 | 0.00x | CA$0.00 | CA$1.27 Million | CA$0.00 | — |